3:21 PM
 | 
Nov 30, 2017
 |  BC Week In Review  |  Company News  |  Deals

Oncodesign leads consortium for AI-based cancer research

In October, Unicancer Group (Paris, France) joined a consortium led by Oncodesign S.A. (Euronext:ALONC) to develop and apply artificial intelligence technology to identify and characterize patients resistant to cancer therapies. France awarded the four-year project, dubbed OncoSNIPE,...

Read the full 161 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >